±Ë¾ç¼º ´ëÀå¿°¿¡¼ Áø´Ü½Ã±âº° ¿¹ÈÄÀÇ Â÷ÀÌ
Differences in the Prognosis according to the Periods of Diagnosis in Ulcerative Colitis
´ëÇѼÒȱâÇÐȸÁö 2014³â 64±Ç 2È£ p.93 ~ p.97
äÇö¹ü(Chae Hyun-Beom) - ¼º±Õ°ü´ëÇб³ ÀÇ°ú´ëÇÐ °ºÏ»ï¼ºº´¿ø ³»°úÇб³½Ç
Á¤À±¼÷(Jung Yoon-Suk) - ¼º±Õ°ü´ëÇб³ ÀÇ°ú´ëÇÐ °ºÏ»ï¼ºº´¿ø ³»°úÇб³½Ç
¹Úµ¿ÀÏ(Park Dong-Il) - ¼º±Õ°ü´ëÇб³ ÀÇ°ú´ëÇÐ °ºÏ»ï¼ºº´¿ø ³»°úÇб³½Ç
ÀÌâ±Õ(Lee Chang-Kyun) - °æÈñ´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
Çã±ÔÂù(Huh Kyu-Chan) - °Ç¾ç´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
½ÅÁ¤Àº(Shin Jeong-Eun) - ´Ü±¹´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
±èÀçÇÐ(Kim Jae-Hak) - µ¿±¹´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
±èÀ¯¼±(Kim You-Sun) - ÀÎÁ¦´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
Á¤À±È£(Jung Yun-Ho) - ¼øõÇâ´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
Á¤¼º¾Ö(Jung Sung-Ae) - ÀÌÈ¿©ÀÚ´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
¼ÛÇöÁÖ(Song Hyun-Joo) - Á¦ÁÖ´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
ÀåÇöÁÖ(Jang Hyun-Joo) - ÇѸ²´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
È«¼º³ë(Hong Sung-Noh) - ¼º±Õ°ü´ëÇб³ ÀÇ°ú´ëÇÐ »ï¼º¼¿ïº´¿ø ³»°úÇб³½Ç
±è¿µÈ£(Kim Young-Ho) - ¼º±Õ°ü´ëÇб³ ÀÇ°ú´ëÇÐ »ï¼º¼¿ïº´¿ø ³»°úÇб³½Ç
Abstract
Background/Aims: Infliximab was approved for the treatment of ulcerative colitis (UC) in 2006 and has recently been used as rescue therapy in steroid-refractory UC. The aim of this study was to investigate the differences of medication use and prognosis in UC patients according to the periods of diagnosis.
Methods: From 1987 to 2012, a total of 1,422 patients with UC were retrospectively reviewed in 12 hospitals. The study population was divided into two groups according to the periods of diagnosis as follows; group A: 1987-2005, group B: 2006-2012. Analyzed variables were compared by using chi-square test and logistic regression analysis.
Results: Mean age of the subjects was 42.2 years, and the mean follow-up period was 4.7 years. In univariate analysis, the use of infliximab in group B was significantly higher than group A (4.5% vs. 7.6%, p=0.016), and UC-related hospitalization (45.8% vs. 40.1%, p=0.031) and UC-related surgery (6.4% vs. 3.5%, p=0.010) in group B was significantly lower than that of group A. The use of oral steroid in surgery group was significantly higher than non-surgery group in multivariate analysis (OR 1.85, 95% CI 1.03-3.30, p=0.039).
Conclusions: Infliximab might play an important role for the treatment of steroid-refractory UC. Well-designed prospective trials based on the efficacy and safety of infliximab are required in the future.
Å°¿öµå
Ulcerative colitis, Infliximab, Steroid, refractory, Surgery
KMID :
0614620140640020093
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)